VSTM Verastem, Inc.
Financings ·
Verastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.
Verastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.
The note purchase agreement allows up to $150.0 million of notes with interest capped at 9.75%. Verastem also sold 1,416,939 shares to Oberland funds at $5.2931 per share and received about $32.3 million in net proceeds from the notes after the Oxford payoff. Its year-end cash figure is unaudited and preliminary.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $30.9 million | $10.0 million |
| Research and development | $114.6 million | $81.3 million |
| Net income (loss) | -$209.5 million | -$130.6 million |
| Cash from operations | -$137.5 million | -$104.8 million |
| Cash and equivalents | $205.0 million | $88.8 million |
Our latest story on this, dated Apr 25, 2025: "Verastem agrees to $75 million private placement of stock and pre-funded warrants". The story links the filing or release it is based on. Read the story.
Verastem, Inc. trades under the ticker VSTM on NASDAQ.
Verastem, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:2VSA; LS:A3EHM3; LSE:0LOV; LSX:A3EHM3.
The SEC Central Index Key (CIK) for Verastem, Inc. is 1526119. Its filings are on SEC EDGAR.
90,563,441 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Verastem, Inc. under United States.
Our directory classifies Verastem, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Verastem, Inc. is US92337C2035.
aibio.space lists Verastem, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as MA.
$30.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Verastem, Inc. reported a net loss of $209.5 million for the fiscal year ended Dec 31, 2025, and used $137.5 million of cash in operations, per its annual report to the SEC.
$114.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
$136.4 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Verastem, dated Apr 25, 2025: "Verastem agrees to $75 million private placement of stock and pre-funded warrants". Verastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock. Source.
Reported a financing. SEC Form 8-K (Items 1.01,2.03,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.02,2.03,3.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio